Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
- PMID: 20129251
- PMCID: PMC2818769
- DOI: 10.1016/j.ccr.2009.12.020
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
Abstract
The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
A simplified approach for molecular classification of glioblastomas (GBMs): experience from a tertiary care center in India.Brain Tumor Pathol. 2016 Jul;33(3):183-90. doi: 10.1007/s10014-016-0251-y. Epub 2016 Feb 10. Brain Tumor Pathol. 2016. PMID: 26865311
-
Molecular classification of glioblastoma based on immunohistochemical expression of EGFR, PDGFRA, NF1, IDH1, p53 and PTEN proteins.Pol J Pathol. 2021;72(1):1-10. doi: 10.5114/pjp.2021.106439. Pol J Pathol. 2021. PMID: 34060283
-
A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.J Genet Genomics. 2017 Nov 20;44(11):519-530. doi: 10.1016/j.jgg.2017.05.007. Epub 2017 Sep 21. J Genet Genomics. 2017. PMID: 29169920
-
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.Neurosurg Focus. 2014 Dec;37(6):E13. doi: 10.3171/2014.9.FOCUS14505. Neurosurg Focus. 2014. PMID: 25434382 Review.
-
Glioblastoma: pathology, molecular mechanisms and markers.Acta Neuropathol. 2015 Jun;129(6):829-48. doi: 10.1007/s00401-015-1432-1. Epub 2015 May 6. Acta Neuropathol. 2015. PMID: 25943888 Review.
Cited by
-
Molecular characterization of gliosarcoma reveals prognostic biomarkers and clinical parallels with glioblastoma.J Neurooncol. 2024 Oct 30. doi: 10.1007/s11060-024-04859-0. Online ahead of print. J Neurooncol. 2024. PMID: 39476147
-
NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.Acta Neuropathol Commun. 2024 Oct 29;12(1):172. doi: 10.1186/s40478-024-01875-z. Acta Neuropathol Commun. 2024. PMID: 39472976 Free PMC article.
-
A method for in silico exploration of potential glioblastoma multiforme attractors using single-cell RNA sequencing.Sci Rep. 2024 Oct 29;14(1):26003. doi: 10.1038/s41598-024-74985-2. Sci Rep. 2024. PMID: 39472601 Free PMC article.
-
Developmental-status-aware transcriptional decomposition establishes a cell state panorama of human cancers.Genome Med. 2024 Oct 28;16(1):124. doi: 10.1186/s13073-024-01393-6. Genome Med. 2024. PMID: 39468667 Free PMC article.
-
Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.J Egypt Natl Canc Inst. 2024 Oct 28;36(1):33. doi: 10.1186/s43046-024-00240-4. J Egypt Natl Canc Inst. 2024. PMID: 39465481 Review.
References
-
- Arjona D, Rey JA, Taylor SM. Early genetic changes involved in low-grade astrocytic tumor development. Curr Mol Med. 2006;6:645–650. - PubMed
-
- Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, Krieg PA, Krupenko SA, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci. 2008;28:264–278. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50CA58223/CA/NCI NIH HHS/United States
- CA127716/CA/NCI NIH HHS/United States
- U24CA126561/CA/NCI NIH HHS/United States
- U54HG003067/HG/NHGRI NIH HHS/United States
- P50 CA058223/CA/NCI NIH HHS/United States
- L30 CA104183-01/CA/NCI NIH HHS/United States
- R01 NS049720/NS/NINDS NIH HHS/United States
- U24 CA126561/CA/NCI NIH HHS/United States
- CA097257/CA/NCI NIH HHS/United States
- NS49720/NS/NINDS NIH HHS/United States
- U54 HG003067/HG/NHGRI NIH HHS/United States
- P50 CA108961/CA/NCI NIH HHS/United States
- U54HG003273/HG/NHGRI NIH HHS/United States
- L30 CA104183-02/CA/NCI NIH HHS/United States
- U24CA126551/CA/NCI NIH HHS/United States
- U24CA126543/CA/NCI NIH HHS/United States
- U24CA126554/CA/NCI NIH HHS/United States
- U24CA126544/CA/NCI NIH HHS/United States
- U24 CA126551/CA/NCI NIH HHS/United States
- CA108961/CA/NCI NIH HHS/United States
- UL1 RR024992/RR/NCRR NIH HHS/United States
- U54 HG003273/HG/NHGRI NIH HHS/United States
- U54HG003079/HG/NHGRI NIH HHS/United States
- U24 CA126554/CA/NCI NIH HHS/United States
- P50 CA097257/CA/NCI NIH HHS/United States
- R01 CA127716/CA/NCI NIH HHS/United States
- U24 CA143848/CA/NCI NIH HHS/United States
- RR023248/RR/NCRR NIH HHS/United States
- U24 CA126543/CA/NCI NIH HHS/United States
- U24CA126563/CA/NCI NIH HHS/United States
- U24CA126546/CA/NCI NIH HHS/United States
- U54 HG003079/HG/NHGRI NIH HHS/United States
- K12 RR023248/RR/NCRR NIH HHS/United States
- U24 CA143867/CA/NCI NIH HHS/United States
- L30 CA104183/CA/NCI NIH HHS/United States
- F30 ES019449/ES/NIEHS NIH HHS/United States
- U24 CA126546/CA/NCI NIH HHS/United States
- U24 CA126563/CA/NCI NIH HHS/United States
- U24 CA126544/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous